Previous 10 | Next 10 |
Biotech Stocks Remain A Core Focus For Traders This Year Penny stocks are well-known for their volatility. In one moment, you can see them gaining hundreds of percentage points. Then the next moment, you see them hitting new lows. Is this the case for all penny stocks ? No, but this...
Pieris Pharmaceuticals (PIRS) has gained ~25.9% in the pre-market after announcing a multi-program research collaboration and license agreement with Genentech, a subsidiary of Roche Holding (RHHBY).The agreement will allow Pieris to combine its proprietary drug discovery w...
AnPac Bio-Medical Science (ANPC) +29% on launching novel Cancer treatment technology and product JV.Pieris Pharmaceuticals (PIRS) +21% on collaboration with Genentech.Ault Global Holdings (DPW) +14% on Q1 results.Taiwan Liposome Company (TLC) +13% as its application for Am...
Pieris will receive $20 million as an upfront payment and is eligible to receive more than $1.4 billion in additional potential milestone payments plus royalties for commercialized programs Collaboration includes initial programs in respiratory disease and ophthalmology, with opportu...
BOSTON, MA / ACCESSWIRE / May 20, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, announced today t...
Pieris Pharmaceuticals, Inc. (PIRS) Q1 2021 Earnings Conference Call May 17, 2021 08:00 AM ET Company Participants Tom Bures - Vice President, Finance Steve Yoder - President & Chief Executive Officer Shane Olwill - Senior Vice President & Head, Translational Science Conference Call P...
Pieris Pharmaceuticals (PIRS): Q1 GAAP EPS of -$0.07 beats by $0.10.Revenue of $15.63M (+17.9% Y/Y) beats by $9.93M.Press Release For further details see: Pieris Pharmaceuticals EPS beats by $0.10, beats on revenue
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON MONDAY, MAY 17, 2021 AT 8:00 AM EDT PRS-060/AZD1402 dosed to first patient in phase 2a study Cinrebafusp alfa (PRS-343) phase 2 study expected to begin this summer Announced license and collaboration agreement with Boston Pharmaceuti...
BOSTON, MA / ACCESSWIRE / May 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced th...
Pieris Pharmaceuticals (PIRS) and Boston Pharmaceuticals have brokered a licensing agreement for the development of PRS-342, a 4-1BB/GPC3 preclinical immuno-oncology bispecific fusion protein.Under the terms of the deal, Pieris will receive an upfront payment of $10M and up to $353M in milest...
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
2024-07-27 03:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 75.8% to $0.0457 on volume of 1,196,767,473 shares NVIDIA Corporation (NVDA) fell 6.8% to $114.25 on volume of 316,196,296 shares Sangamo Therapeutics Inc. (SGMO) rose 39.5% to $0.56 on volume of 261...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...